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The opportunistic bacteria of the Burkholderia cepacia complex (Bcc) are extremely pathogenic to cystic fibrosis (CF) patients,
and acquisition of Bcc bacteria is associated with a significant increase in mortality. Treatment of Bcc infections is difficult be-
cause the bacteria are multidrug resistant and able to survive in biofilms. Short palate, lung, and nasal epithelial clone 1
(SPLUNC1) is an innate defense protein that is secreted by the upper airways and pharynx.While SPLUNC1 is known to have
antimicrobial functions, its effects on Bcc strains are unclear. We therefore tested the hypothesis that SPLUNC1 is able to impair
Bcc growth and biofilm formation.We found that SPLUNC1 exerted bacteriostatic effects against several Bcc clinical isolates,
including B. cenocepacia strain J2315 (50% inhibitory concentration [IC50] 0.28M), and reduced biofilm formation and at-
tachment (IC50 0.11M).We then determined which domains of SPLUNC1 are responsible for its antimicrobial activity. De-
letions of SPLUNC1’s N terminus and 6 helix did not affect its function. However, deletion of the 4 helix attenuated antimi-
crobial activity, while the corresponding 4 peptide displayed antimicrobial activity. Chronic neutrophilia is a hallmark of CF
lung disease, and neutrophil elastase (NE) cleaves SPLUNC1. However, we found that the ability of SPLUNC1 to disrupt biofilm
formation was significantly potentiated by NE pretreatment. While the impact of CF on SPLUNC1-Bcc interactions is not cur-
rently known, our data suggest that understanding this interactionmay have important implications for CF lung disease.
The Burkholderia cepacia complex (Bcc) is comprised of 18Gram-negative bacteria that, while phenotypically similar, are
genetically distinct species (1–3). Although Bcc strains are com-
monly found in the environment, Bcc bacteria are a group of
opportunistic pathogens associated with immunocompromised
patients, such as those with cystic fibrosis (CF) (4, 5). Unlike Pseu-
domonas aeruginosa infections, which usually result in a relatively
slow decline in CF lung function (6), Bcc infections are unusually
virulent and are associated with a rapid decline in CF life expec-
tancy (7, 8). Indeed, Bcc infections result in “cepacia syndrome,”
which is characterized by pneumonia, deteriorating lung func-
tion, bacteremia, and increased mortality (9, 10). Treatment of
Bcc infections is difficult because these pathogens are resistant to
many antibiotics, including polymyxins, trimethoprim, quino-
lones,-lactams, chloramphenicol, aminoglycosides, and antimi-
crobial peptides (11–13). Bcc infection is usually planktonic and
invasive, and the bacteria survive intracellularly in pulmonary
macrophages and respiratory epithelial cells (14, 15). Although
biofilms are not typically observed, Bcc bacteria have been shown
to form biofilms in vitro and to form mixed biofilms when cul-
tured with P. aeruginosa (16–18). In addition, Bcc biofilms are
more resistant to antibiotic cocktails than P. aeruginosa biofilms
(19).
Short palate, lung, and nasal epithelial clone 1 (SPLUNC1) is a
25-kDa protein that is primarily secreted by the airways and na-
sopharynx (20). SPLUNC1, also known as PLUNC (palate, lung,
and nasal epithelium clone), SPURT (secretory protein in upper
respiratory tracts), LUNX (lung-specific X protein), NASG (naso-
pharyngeal carcinoma-related protein), and BPIFA1 (BPI fold-
containing family A member 1), has also been found in saliva and
nasal lavage fluids from healthy individuals, at concentrations
ranging from 0.4 to 10 M (21), and its expression levels increase
greatly with inflammation (22, 23). SPLUNC1 is a multifunctional
protein that regulates the epithelial sodium channel (ENaC) to
modulate airway hydration levels (24, 25) as well as having surfac-
tant-like properties and antimicrobial actions (21, 26). For exam-
ple, SPLUNC1 is part of the bactericidal permeability-increasing
(BPI) protein family (27) and has structural similarities to the BPI
protein (28, 29). As part of the innate immune response to infec-
tions, SPLUNC1 has been shown to have antimicrobial and anti-
biofilm activities against many Gram-negative bacteria. Further-
more, SPLUNC1 knockout mice are more susceptible to Klebsiella
pneumoniae and P. aeruginosa infections (26, 30). While
SPLUNC1 has antimicrobial activity against P. aeruginosa, Hae-
mophilus influenzae, and K. pneumoniae (22, 26, 30, 31), its effects
against Bcc strains have only recently been examined and are not
fully understood (32).
Airway epithelia utilize several host defense mechanisms, in-
cluding mucociliary clearance (MCC), antimicrobial peptides,
oxidative bursts, proteases, cytokines, and growth factors, to re-
duce bacterial invasion (15, 33–35). For example, Bcc infection
stimulates inflammatory responses resulting in neutrophil influx
into the lung (9, 36). CF airways have chronic inflammation and
increased levels of cytokines, such as interleukin-1 (IL-1), IL-6,
IL-8, and tumor necrosis factor alpha, as well as chronic neutro-
philia and increased protease activity in the lung lumen, including
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increased neutrophil elastase (NE) activity (37, 38). Although NE
is needed for killing of Gram-negative bacteria (39), increased
levels of NE have been shown to cleave SPLUNC1 and have been
proposed to impair airway epithelial defenses (25, 31). We re-
cently showed that SPLUNC1 affects Burkholderia cenocepacia
J2315 (32). However, little is known about SPLUNC1’s ability to
affect different Bcc strains. Since SPLUNC1 is the most abun-
dantly expressed protein in the airways (29), we sought to fully
understand its interaction with Bcc strains as a first step toward
developing novel antibiotics against Bcc bacteria for the treatment
of CF. In this study, we therefore tested SPLUNC1’s antimicrobial
activity against Bcc clinical isolates under planktonic and biofilm
conditions. In addition, we tested the antimicrobial and antibio-
film effects of SPLUNC1 exposed to NE.
MATERIALS AND METHODS
Bacterial strains andmedia.Bcc clinical isolates (Table 1) (obtained from
John J. Lipuma, CFF Burkholderia cepacia Research Laboratory and Re-
pository, University of Michigan Medical School), except for Bcc isolate
K56-2 and the hldE and wbxE mutants (obtained from Miguel A. Val-
vano, Queens University, Belfast, Northern Ireland), P. aeruginosa PAO1,
and Staphylococcus aureus CDL (obtained from Matthew Wolfgang, Uni-
versity of North Carolina at Chapel Hill) were grown in Luria broth (LB)
at 37°C for 24 h with shaking at 300 rpm. The number of CFU per milliliter
was determined by serial dilution plating on LB agar plates.
SPLUNC1 proteins. A plasmid containing SPLUNC1 cDNA was
transformed into BL21-Codon Plus competent cells (Agilent Technolo-
gies) and purified as previously described (40). After purification, all re-
combinant SPLUNC1 proteins were produced as described previously
and stored at 80°C until required (40). The recombinant SPLUNC1
proteins included 19 SPLUNC1 (referred to as SPLUNC1), which lacks
the cleavable N-terminal signal sequence (residues M1 to M19) but is
otherwise full length; the S18 peptide, which corresponds to residues G22
to A39; the 44 mutant (residues T45 to V256), which lacks residues M1
to S43, including the S18/G22-to-A39 region; the 4 helix peptide (resi-
dues K77 to L101); the4 mutant, which lacks the4 helix (residues I76
to I105 and includes nonnative Gly-Ser-Gly-Ser linker to residues L75 to
I106); the 6 helix peptide (residues I252 to V256); and the 6 mutant,
which lacks the 6 helix (residues I242 to V256).
Antimicrobial assay. The antimicrobial activity of SPLUNC1 was
tested by incubating Bcc strains in the presence of various concentrations
of SPLUNC1 or SPLUNC1 mutants. The bacterial cultures were grown
overnight at 37°C and 300 rpm. After 24 h, bacteria at 106 CFU/ml were
added to round-bottomed 96-well plates (Corning Incorporated) with
increasing doses of SPLUNC1. Plates were incubated at 37°C for 24 h, and
bacterial growth was measured by determining the optical density at 600
nm (OD600) by using a Tecan Sunrise plate reader. Samples were also
collected at 24 h, serially diluted in Ringer’s solution, and plated on LB
agar plates to determine the number of CFU per milliliter. Percent inhi-
bition was then determined using the following equation: % inhibition
[(CFU/ml from vehicle  CFU/ml from SPLUNC1 present)/(CFU/ml
from vehicle)] 100.
Antibiofilm assay. The antibiofilm activity of SPLUNC1 was tested by
incubating Bcc strains in the presence of increasing concentrations of
SPLUNC1 or SPLUNC1 mutants. For biofilm inhibition, SPLUNC1 was
coincubated with 106 CFU/ml Bcc strains in flat-bottomed 96-well plates
for 24 h. For disruption of biofilms, bacteria at 106 CFU/ml were added to
flat-bottomed 96-well plates and incubated for 24 h for biofilm formation,
and 0.4 M SPLUNC1 was then added for a further 1 or 24 h. Plates were
incubated at 37°C and then washed. Biofilms were fixed with methanol
and stained with 1% crystal violet. After rinsing with distilled water, the
stained biofilms were resolubilized with 33% acetic acid. Biofilm forma-
tion was measured by determining the OD590 by using a Tecan Sunrise
plate reader.
Attachment assay. Bcc cultures were grown overnight, adjusted to an
OD600 of 1.0, and added to flat-bottomed 96-well plates. SPLUNC1 was
added at 0.4M and incubated for 1 to 3 h. Attachment was measured by
1% crystal violet staining and determination of the OD590 as previously
described (41).
Cleavage of SPLUNC1 by proteases. SPLUNC1 (40 M) was incu-
bated alone or with 1 M neutrophil elastase (NE; Elastin Product Com-
pany) at 37°C for up to 24 h. NE alone (1 M) was used as a control. To
stop NE activity, 1 M sivelestat (NE inhibitor ONO5046; Sigma) was
added, and the samples were placed immediately on ice. An aliquot of the
sample was denatured and run in a 4 to 15% Mini-Protean TGX SDS-
PAGE gel (Bio-Rad). Gels were stained by Coomassie brilliant blue R-250
(Thermo Scientific) and visualized by a Bio-Rad Chemidoc instrument.
To test for antimicrobial and antibiofilm activities, samples were then
diluted 1:100, to a final concentration of 0.4 M, and incubated with 106
CFU/ml B. cenocepacia J2315 for 24 h at 37°C. Bacterial growth and bio-
film formation were measured as described above.
Neutrophil elastase activity assay. Inhibition of NE activity by sive-
lestat was confirmed by incubating 1M NE and 10M Suc-Ala-Ala-Ala-
MCA substrate (MAA-3133-v; Peptides International) with or without 1
M sivelestat for 90 min at 37°C. Substrate fluorescence was measured
every 5 min as an indicator of NE activity at excitation/emission wave-
lengths of 380/460 nm, using a Tecan Infinite M1000 multiplate reader.
Multiangle static light scattering. SPLUNC1 (5 mg/ml) was treated
with 5M NE in 50 mM HEPES, 150 mM NaCl, pH 7.4, and 0.02% azide
for up to 24 h at 37°C, and the treatment was stopped with 1.25 M
sivelestat. Samples were injected onto a GE Superdex S200 size-exclusion
column connected to a multiangle light scattering instrument (Dawn
EOS; Wyatt Technologies) and a refractometer (Optilab T-rEX; Wyatt
Technologies). The molecular weight of the sample eluting for each peak
was calculated based on light scattering and refractive index data by using
the ASTRA 6 software package (Wyatt Technologies). A dn/dc value of
0.185 was assumed.
Circular dichroism. SPLUNC1 was placed in circular dichroism (CD)
buffer containing 10 mM potassium phosphate (pH 7.4) and 150 mM
potassium fluoride. SPLUNC1 (40 M) was treated with 1 M NE for
various times, and then NE was inhibited with 1 M sivelestat. Samples
were diluted to 10 M in the buffer described above and loaded into
1-mm cuvettes. Using a Chirascan-Plus instrument (Applied Photophysis
Limited), spectra were recorded from 185 to 280 nm at 20	 1.0°C. Mea-
surements were corrected for the background signal by using CD buffer
containing 1 M NE and 1 M sivelestat without SPLUNC1.
TABLE 1 Burkholderia cepacia complex clinical isolates used in this
study
Species Isolate
B. cenocepacia GIIIb PHDC
AU19445
AU20454
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Statistical analysis. All data are shown as means 	 standard errors.
Data were analyzed using Prism software (GraphPad Software, Inc.).
Nonparametric one-way analysis of variance (ANOVA; Kruskal Wallis)
was used to compare multiple groups. P values of
0.05 were considered
statistically significant. All experiments were performed a minimum of
three times.
RESULTS
Antimicrobial activity of SPLUNC1 against Bcc strains. The Bcc
epidemic Edinburg-Toronto (ET)-12 strain B. cenocepacia J2315
is known to cause cepacia syndrome (42). Therefore, SPLUNC1’s
antimicrobial effects were initially tested against this strain in a
dose-dependent manner. SPLUNC1 was found to have antimi-
crobial activity against J2315, with a 50% inhibitory concentration
(IC50  0.28 M) similar to that observed for P. aeruginosa
(IC50 0.12 M) (Fig. 1A). We next tested SPLUNC1’s ability to
affect a Gram-positive bacterium (S. aureus). Consistent with pre-
vious reports that SPLUNC1 affects only Gram-negative bacteria
(22, 30), S. aureus was insensitive to SPLUNC1. We also found
that SPLUNC1 was more potent than tobramycin (IC50  0.33
M) to reduce growth of J2315, while the antibiotic polymyxin B,
to which B. cenocepacia is resistant, had relatively little effect
(Fig. 1B) (43). To test SPLUNC1’s ability to affect the growth of
other Bcc clinical isolates, a physiological concentration of 0.4M
SPLUNC1, which is comparable to that found in nasal and saliva
lavage fluids from healthy humans (21), was added along with Bcc
clinical isolates at time zero, and bacterial growth was determined
24 h later. The data indicate that SPLUNC1 significantly affected
the growth of many, but not all, of the Bcc clinical isolates that
were tested (Fig. 1C to E). Increasing concentrations of up to 4M
SPLUNC1 were also tested against the Bcc clinical isolates that
were not initially susceptible, and these isolates remained insensi-
tive to SPLUNC1 (n  3) (data not shown). These data suggest
that susceptibility to SPLUNC1 is strain dependent. SPLUNC1
has previously been shown to bind to bacterial lipopolysaccharide
(LPS) (22, 32). The LPS composition varies between the different
Bcc strains, which may alter its susceptibility to SPLUNC1. To
determine if the different LPS structures of Bcc strains play a role
in their susceptibility to SPLUNC1, we used the B. cenocepacia
K56-2 strain and its hldE and wbxE LPS mutants. The hldE
gene codes for a heptokinase and is required for the assembly of
the inner core oligosaccharide region of LPS, while the wbxE gene
encodes a glycosyltransferase that mediates assembly of the O-an-
tigen subunits (44). SPLUNC1 (0.4 M) reduced the bacterial
growth of wild-type K56-2 to a degree similar to that for J2315
(Fig. 1F). While the wbxE mutant was susceptible to 0.4 M
SPLUNC1, growth of the hldE mutant was unaffected by
FIG 1 SPLUNC1 has antimicrobial activity against B. cepacia complex clinical isolates. (A) SPLUNC1 was coincubated with 106 CFU/ml B. cenocepacia J2315
(), P. aeruginosa PAO1 (), or S. aureus CDL (Œ) for 24 h, and growth was measured. The number of CFU per milliliter was determined, and inhibition was
calculated as follows: % inhibition  [(CFU/ml from vehicle  CFU/ml from SPLUNC1 present)/(CFU/ml from vehicle)]  100. (B) SPLUNC1 (),
tobramycin (Œ), and polymyxin B (o) were incubated with 106 CFU/ml J2315 for 24 h, and growth was measured. (C to E) SPLUNC1 (0.4 M) was incubated
for 24 h with 106 CFU/ml of B. cenocepacia (C), B. cepacia (D), and Burkholderia multivorans (E) isolates, and growth was measured. (F) SPLUNC1 (0.4M) was
incubated for 24 h with 106 CFU/ml of B. cenocepacia K56-2 and its wbxE and hldE LPS mutants, and growth was measured. Open bars, vehicle; closed bars,
0.4 M SPLUNC1. *, P
 0.05; **, P
 0.01; ***, P
 0.001 (n 4 for all panels).
Burkholderia and SPLUNC1 Interactions
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SPLUNC1, suggesting that different regions of the LPS structure
play a role in SPLUNC1 susceptibility.
SPLUNC1 has bacteriostatic activity against B. cenocepacia
J2315. To better understand SPLUNC1’s effects on Bcc strains, we
subsequently focused on its effects on the epidemic strain J2315
(42). As growth was still seen after 24 h, even with higher concen-
trations of SPLUNC1 (Fig. 1A), we next determined whether
SPLUNC1 also exerted bacteriostatic and/or bactericidal activity
against J2315. We therefore incubated this strain with or without
0.4 M SPLUNC1 for 2 h. Bacteria were then washed with 0.1%
Triton X-100 to remove SPLUNC1 and grown for an additional 9
h. In the presence of SPLUNC1, bacterial growth was inhibited at
2 h. However, after removal of SPLUNC1, bacterial growth re-
sumed, reaching levels similar to those of nontreated J2315 (Fig.
2). In addition, after 24 h, some J2315 bacteria were still present in
the medium (Fig. 1B), suggesting that SPLUNC1 has bacterio-
static rather than bactericidal activity.
SPLUNC1 has antibiofilm activity against Bcc strains.
SPLUNC1 has previously been shown to exhibit antibiofilm activ-
ity against Gram-negative bacteria (22, 30, 32). To determine
whether SPLUNC1 exerts antibiofilm activity against B. cenocepa-
cia, increasing concentrations of SPLUNC1 were coincubated
with 106 CFU/ml J2315 for 24 h. Biofilm biomass was then mea-
sured by crystal violet staining. Our data indicated that SPLUNC1
prevented J2315 biofilm formation, with an IC50 of 0.10 M (Fig.
3A). To determine if SPLUNC1 also affected preformed biofilms,
J2315 was grown for 24 h to allow for biofilm formation, and
SPLUNC1 was added over a range of concentrations to the pre-
formed biofilms and incubated for 1 h and 24 h. We found that
SPLUNC1 significantly reduced preformed J2315 biofilms after
both 1 h and 24 h (Fig. 3B), therefore suggesting that SPLUNC1
can exert antibiofilm activity.
Bacterial attachment is the first step in biofilm formation; we
therefore tested whether SPLUNC1 affected biofilm attachment.
In addition to reducing biofilm formation, 0.4M SPLUNC1 also
inhibited initial J2315 attachment for up to 3 h (Fig. 3C), suggest-
ing an additional role for SPLUNC1 in biofilm inhibition.
Since SPLUNC1’s antimicrobial activities against the various
Bcc clinical strains differed, its antibiofilm activities against these
strains were also tested. At 0.4 M, SPLUNC1 reduced some but
not all Bcc biofilm biomass (Fig. 3D to F). Increasing concentra-
tions of up to 4 M SPLUNC1 were also tested against the Bcc
clinical isolates that were not initially susceptible. However, these
strains remained insensitive to SPLUNC1, suggesting that
SPLUNC1’s antibiofilm activity is also strain specific (n 3) (data
not shown). Additionally, while B. cenocepacia strains PHDC,
AU20454, and AU21968 were resistant to SPLUNC1’s antimicro-
bial activity (Fig. 1C), they were susceptible to SPLUNC1’s anti-
biofilm activity (Fig. 3D). Since LPS plays a role in Bcc strain
susceptibility to SPLUNC1’s antimicrobial activity (Fig. 1F), it
may also be involved in susceptibility to SPLUNC1’s antibiofilm
activity. While 0.4 M SPLUNC1 reduced the K56-2 biofilm bio-
mass to levels similar to those for J2315, its effects on the hldE
andwbxE LPS mutants varied (Fig. 3E). However, in contrast to
the antimicrobial activity results, SPLUNC1 reduced hldE bio-
film biomass but did not affectwbxE biofilm biomass, suggesting
that different regions of LPS are involved in Bcc strain suscepti-
bility to SPLUNC1’s antibiofilm activity.
SPLUNC1mutants reduce growth and biofilm formation of
B. cenocepacia J2315. Since SPLUNC1 was effective against
J2315, we then sought to determine which domains of SPLUNC1
were responsible for its antimicrobial activity. SPLUNC1’s N-ter-
minal S18 region is responsible for regulating ENaC (25), and we
recently showed that deletion of the 4 helix resulted in attenu-
ated antimicrobial activity (32). However, the following addi-
tional peptides and mutants of SPLUNC1 were generated to test
whether the antimicrobial and antibiofilm activities were localized
to a specific region of SPLUNC1: (i) the S18 peptide (residues G22
to A39), an N-terminal region containing only the ENaC inhibi-
tory domain; (ii) the 44 mutant (residues T45 to V256), which
lacks the SPLUNC1 N terminus, including the S18 region; (iii) the
4 mutant, which lacks the 4 helix (residues I76 to I105 and
includes nonnative Gly-Ser-Gly-Ser linker to L75 to I106); (iv) a
peptide corresponding to the 4 helix (residues K77 to L101); (v)
the 6 mutant, in which the 6 helix (residues I242 to V256) is
absent; and (vi) the 6 helix peptide (residues I242 to V256) (Fig.
4A). The 4 and 6 mutants were chosen because (i) 4 and
6 are two novel helixes that were present in our SPLUNC1 crystal
structure and do not share homology with BPI (40) and (ii) our
previous studies demonstrated that deletion of the 4 helix re-
duced SPLUNC1’s antimicrobial effects (32). SPLUNC1 mutants
were coincubated with 106 CFU/ml J2315 for 24 h, and bacterial
growth and biofilm biomass were determined (Fig. 4B and C). The
S18 peptide exhibited neither antimicrobial nor antibiofilm activ-
ity against J2315. Consistent with this observation, the 44 mu-
tant retained full antimicrobial activity (IC50  0.14 M) and
antibiofilm activity (IC50 0.12M). The helix mutants varied in
their effects against J2315. The 4 mutant lost antimicrobial
activity against J2315 and also had significantly diminished anti-
biofilm activity (IC50 0.46 M). However, the 4 peptide pos-
sessed antimicrobial activity against J2315 (IC50  0.36 M) but
did not have antibiofilm activity (Fig. 4B and C). The6 mutant
retained its antimicrobial activity (IC50  0.15 M) but had sig-
nificantly reduced antibiofilm activity (IC50 0.24M), while the
6 peptide had neither antimicrobial nor antibiofilm activity
against J2315 (Fig. 4B and C).
Neutrophil elastasemaintains SPLUNC1’s antibiofilmactiv-
ity. Chronic neutrophilia is a hallmark of CF lung disease and
leads to elevated levels of NE in the lung lumen (45). SPLUNC1 is
known to be a substrate for NE, and in some cases, NE may alter
FIG 2 SPLUNC1 is bacteriostatic, not bactericidal. B. cenocepacia J2315 was
incubated with or without 0.4 M SPLUNC1 for 2 h (starting at2 h). Bac-
teria were then washed at 0 h with 0.1% Triton X-100 to remove SPLUNC1,
grown for an additional 9 h, and measured by determining the OD600 every 3 h.
Open bars, vehicle; closed bars, 0.4 M SPLUNC1. *, P 
 0.05 compared to
vehicle at 2 h; **, P 
 0.01 compared to vehicle at 2 h; , P 
 0.01
compared to 0.4 M SPLUNC1 at2 h (n 3).
Ahmad et al.
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SPLUNC1’s activity (25, 31, 46). To determine the effects of NE
cleavage on SPLUNC1’s antimicrobial and antibiofilm activities,
SPLUNC1 was exposed to 1 M NE for defined periods, after
which NE activity was inhibited by sivelestat as previously re-
ported (47). SPLUNC1 was extensively cleaved by NE, as shown
by SDS-PAGE followed by Coomassie blue staining (Fig. 5A). In-
hibition of NE by sivelestat was then confirmed by measuring the
ability of NE to cleave the fluorogenic substrate Suc-Ala-Ala-Ala-
MCA (Fig. 5B). SDS-PAGE fully denatures SPLUNC1, allowing
individual fragments to be separated by size. However, under the
nondenaturing conditions seen in the airways, NE cleavage of
SPLUNC1 may not result in its dissociation, and SPLUNC1 may
remain cohesive in the airway surface liquid (ASL) after cleavage.
To determine if SPLUNC1 remained intact after NE exposure, we
measured SPLUNC1’s molecular size in a physiological solution
after NE exposure by multiangle static light scattering. Molecular
mass was determined by measuring the intensity of scattered light
against SPLUNC1. SPLUNC1’s initial (0 h) molecular mass was
FIG 3 SPLUNC1 has antibiofilm activity against Bcc strains. (A) Dose-response curve for SPLUNC1 coincubated with 106 CFU/ml B. cenocepacia J2315 for 24 h.
(B) Preformed (24 h) J2315 biofilms were incubated with increasing concentrations of SPLUNC1 for 1 h () or 24 h (Œ). (C) Attachment assay for J2315
coincubated with 0.4 M SPLUNC1 for up to 3 h. (D to F) SPLUNC1 (0.4 M) was coincubated for 24 h with B. cenocepacia (D), B. cepacia (E), and B.
multivorans (F) Bcc clinical isolates. (G) SPLUNC1 (0.4 M) was incubated for 24 h with 106 CFU/ml of B. cenocepacia K56-2 and its wbxE and hldE LPS
mutants. Bcc strains were stained with 1% crystal violet and measured by determining the OD590, and inhibition was calculated as follows: % inhibition 
[(CFU/ml from vehicle CFU/ml from SPLUNC1 present)/(CFU/ml from vehicle)] 100. Open bars, vehicle; closed bars, 0.4M SPLUNC1. *, P
 0.05; **,
P
 0.01 (n 4 for all panels).
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23.5 kDa (Fig. 5C). After a 1-h exposure to NE, SPLUNC1’s mo-
lecular mass was 22.3 kDa. There was a slight reduction in molec-
ular mass within the initial 6 h after NE exposure, to 19.6 kDa.
After 24 h of exposure to NE, SPLUNC1’s molecular mass further
decreased, to 18.6 kDa. However, these sizes were still greater than
those of the individual fragments detected by SDS-PAGE (15 to
17 kDa) (Fig. 5A). To further examine changes in SPLUNC1’s
structure after NE exposure, cleaved SPLUNC1 was analyzed by
circular dichroism (CD) spectroscopy in the far-UV spectral re-
gion (190 to 250 nm) to observe SPLUNC1’s secondary structures.
SPLUNC1 initially had a secondary alpha-helical structure, as in-
dicated by a positive signal at 194 nm and two small negative
signals, at 208 and 222 nm (Fig. 5D). Despite being cleaved by NE,
SPLUNC1 retained its secondary alpha-helical structure for up to
12 h, but it lost this structure after 24 h of incubation with NE, as
shown by a random coiling effect, with a negative signal at 200 nm
and an increasing signal at 210 nm.
We next tested cleaved SPLUNC1, created by timed incuba-
tions with NE, for antimicrobial and antibiofilm activities by
coincubation with 106 CFU/ml J2315 for 24 h. NE-exposed
SPLUNC1 had increased antimicrobial and antibiofilm activities
against J2315 compared to those of SPLUNC1 alone (Fig. 6A and
B). However, after 24 h, NE-exposed SPLUNC1 had levels of an-
timicrobial activity similar to those of SPLUNC1 alone. Surpris-
ingly, the effect of SPLUNC1 to disrupt biofilm formation was
significantly potentiated by NE pretreatment for up to 12 h (n 3;
P 
 0.01) (Fig. 6B). Importantly, these effects were not due to
active NE, since NE activity had been halted by sivelestat (Fig. 5B).
As a control, we tested the effects of NE plus sivelestat against
J2315 growth, and these compounds had no antimicrobial or an-
tibiofilm activity (Fig. 6C and D).
DISCUSSION
The airways contain many antimicrobial agents, including pep-
tides, such as cathelicidins and -defensins, and proteins, includ-
ing SPLUNC1, as part of the first line of innate defense against
pathogens (27, 33). Previous reports showed that knockout of
SPLUNC1 in mice led to increases in bacterial infections by P.
aeruginosa, K. pneumoniae, and H. influenzae (26, 30, 31), suggest-
ing that SPLUNC1 plays an important role in reducing bacterial
infections. Furthermore, 0.4M SPLUNC1 reduced P. aeruginosa
growth by 80% in vitro (48). While Bcc growth is not affected by
cathelicidins or -defensins (49), our results show that 0.4 M
SPLUNC1, which is within the physiological range of SPLUNC1
in the ASL (0.4 to 1 M), also reduces J2315 growth (Fig. 1A and
B) (22). SPLUNC1 is thought to exert its antimicrobial activity
against P. aeruginosa by formation of pores in the bacterial cell
wall, thus increasing cell wall permeability (22). SPLUNC1 shares
structural homology with BPI and binds through hydrophobic
interactions with the LPS of Gram-negative bacteria, such as K.
pneumoniae and P. aeruginosa (50). Despite being structurally
smaller than BPI, SPLUNC1 is thought to have similar mecha-
nisms of interaction with P. aeruginosa (22). Although J2315 was
FIG 4 The4 helix is required for SPLUNC1’s antimicrobial activity against B. cenocepacia J2315. (A) Three-dimensional rendering of SPLUNC1 structure with
the intrinsically disordered S18 region appended (labeled in red). Also indicated are 44 SPLUNC1, which lacks the S18 region (blue arrow); the 4 region
(labeled in purple), which is absent in the 4 mutant; and the 6 region (labeled in green), which is absent in the 6 mutant. Increasing concentrations of
SPLUNC1 (black closed circles), the 44 (blue closed squares), 4 (purple closed squares), and 6 (green closed triangles) SPLUNC1 mutants, and the 4
(purple open squares), 6 (green open triangles), and S18 (red closed triangles) peptides were coincubated with 106 CFU/ml J2315 for 24 h and measured for
antimicrobial activity by CFU counts and calculation of % growth inhibition as previously described (B) and for antibiofilm activity by 1% crystal violet staining,
OD590 reading, and calculation of % biofilm biomass inhibition as previously described (C). **,P
 0.001 for S18 peptide compared to SPLUNC1; ***,P
 0.0001
for S18 peptide compared to SPLUNC1;, P
 0.001 for 4 mutant compared to SPLUNC1;, P
 0.0001 for 4 mutant compared to SPLUNC1;
#, P 
 0.01 for 6 mutant compared to SPLUNC1; , P 
 0.05 for 4 peptide compared to SPLUNC1; , P 
 0.001 for 4 peptide compared to
SPLUNC1; °, P
 0.05 for 6 peptide compared to SPLUNC1; °°°, P
 0.001 for 6 peptide compared to SPLUNC1 (n 3 for all panels).
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susceptible to SPLUNC1, SPLUNC1’s antimicrobial activity var-
ied among the different Bcc species (Fig. 1C to E). This variation in
susceptibility among the different Bcc species may be due to the
unusual composition of the LPS structure, which differs among
the Bcc species (51). Indeed, susceptibility to other antibiotics has
been reported to vary among the Bcc members (11, 52). Our re-
sults demonstrate that changes to Bcc strains’ LPS structure alter
their susceptibility to SPLUNC1 (Fig. 1F and 3E). As LPS plays an
important role in bacterial sensitivity to antimicrobial agents,
more studies will be needed to compare the LPS structures of these
strains to determine their interaction with SPLUNC1.
Researchers have proposed that the ASL is bacteriostatic rather
than bactericidal (53–55) and must act in concert with functional
mucociliary clearance (MCC) to remove bacteria. That is, as bac-
terial growth is impaired, MCC removes the bacteria in the air-
ways, preventing bacterial colonization (56). SPLUNC1 has been
shown to coat P. aeruginosa to inhibit growth rather than killing
bacteria (22, 32). Indeed, our results revealed that when
SPLUNC1 was removed, J2315 growth was restored to levels sim-
ilar to those of the controls (Fig. 2), confirming that SPLUNC1
also has bacteriostatic activity against Bcc strains.
In order to determine which domain of SPLUNC1 is required
for its antimicrobial activity, SPLUNC1 mutants and peptides
were tested. The S18 peptide exerted neither antimicrobial nor
antibiofilm activity against J2315. The 44 mutant, which lacks
the S18 region, had antimicrobial and antibiofilm activities com-
parable to those of full-length SPLUNC1. Although the S18 region
does not exert antimicrobial or antibiofilm activity against J2315,
since this region is required to regulate ENaC (25), it still plays a
role in mechanically clearing bacteria via the mucociliary escalator
in vivo. Deletion of the 4 but not 6 helix resulted in a loss of
antimicrobial activity. Consistent with this observation, the 4
peptide restored antimicrobial activity, suggesting that this region
of SPLUNC1 is absolutely required for SPLUNC1’s antimicrobial
activity. In addition, both the 4 and 6 mutants had reduced
biofilm activity, but here it was less clear, since the 4 deletion
exerted a much stronger effect than the 6 deletion. In addition,
the 4 and 6 peptides alone did not exert antibiofilm activity.
However, it is likely that these helixes both play roles in
SPLUNC1’s antibiofilm activity while present in the SPLUNC1
protein (Fig. 4). While the 44 mutant retained antimicrobial
activity (Fig. 4B), other SPLUNC1 fragments formed by NE activ-
ity may further expose the domains for antimicrobial and anti-
biofilm activities of SPLUNC1 for enhancement of the reduction
of J2315 growth and biofilm formation.
Although biofilms in CF patients are rare, Bcc strains have been
shown to form biofilms in vitro and to form thick biofilms in sputa
of CF patients (57–59). Biofilms increase the bacterium’s antibi-
otic resistance. However, we found that 0.4 M SPLUNC1 both
prevents biofilm formation and reduces preformed J2315 biofilms
(Fig. 3A and B). Surfactants change flagellar development, leading
to altered bacterial attachment and altered biofilm formation (30,
60). SPLUNC1 has surfactant activity (21, 32), which may play a
role in antibiofilm activity. Indeed, our results have shown that
SPLUNC1 reduces J2315 attachment (Fig. 3C), and we speculate
that SPLUNC1’s surfactant activities may play a role in antibiofilm
activity against Bcc strains. Additionally, SPLUNC1’s antibiofilm
activity varied among the Bcc clinical isolates (Fig. 3D and E), as
was seen with SPLUNC1’s antimicrobial activity (Fig. 1C to E),
which may be due to differences in the LPS or flagellar proteins of
Bcc clinical isolates.
Persistent bacterial infection in CF lungs leads to airway
FIG 5 SPLUNC1 does not dissociate and retains secondary structure after cleavage with NE. (A) Time course showing cleavage of 40 M SPLUNC1 by 1 M
NE by SDS-PAGE with Coomassie blue staining. (B) Inhibition of 1 M NE activity without () or with () 1 M sivelestat and 10 M substrate (Suc-Ala-
Ala-Ala-MCA protein) (error bars are obscured by the symbols). A.U., arbitrary units. (C) Static light scattering of SPLUNC1 before and at timed intervals after
exposure to NE and sivelestat. (D) Circular dichroism analysis of SPLUNC1 before and at timed intervals after exposure to NE and sivelestat. *, P
 0.01; **, P

0.001 (n 3 for all panels).
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inflammation, chronic neutrophilia, increased protease activ-
ity, and subsequent lung damage (23, 37, 61). NE readily
cleaves SPLUNC1. However, we previously showed that the
S18 peptide, which is analogous to SPLUNC1’s ENaC inhibi-
tory domain, remains as an intact and functional peptide capa-
ble of regulating ENaC even after NE exposure (25). Con-
versely, Jiang et al. reported that addition of NE to normal
human tracheobronchial epithelia impaired their antimicro-
bial activity against Mycoplasma pneumoniae and H. influenzae
(31). Here we found that NE-cleaved SPLUNC1 maintains anti-
microbial/antibiofilm activity for up to 24 h against J2315 and that
this activity is significantly enhanced compared to that of whole
SPLUNC1 for a limited period (Fig. 6A and B). During the early
stages of infection, both SPLUNC1 and NE expression levels in-
crease (22, 23, 37), which may serve to potentiate SPLUNC1’s
antimicrobial activities, leading to a quicker resolution of the in-
fection. However, in CF airways, SPLUNC1 is inactive due to the
acidic environment, leading to a failure to regulate ENaC and to
clear mucus, and chronic neutrophilia occurs, resulting in in-
creased NE levels (29, 37, 40). We noted that the beneficial effects
of NE on SPLUNC1 were eventually abolished (Fig. 6). Chroni-
cally increased NE levels may therefore lead to an altered ASL
milieu that contributes to SPLUNC1’s degradation and further
impairment of SPLUNC1’s antimicrobial activities (31). Indeed,
we previously reported that SPLUNC1 is differentially cleaved in
CF versus normal sputum (25). Our data indicate that as NE ini-
tially cleaves SPLUNC1, SPLUNC1 initially retains its secondary
alpha-helical structure (Fig. 5D), which may allow the protein to
continue to exert antimicrobial activity against J2315 as well as
releasing the S18 peptide, which can help to flush out the airways
by inhibiting ENaC and increasing hydration and MCC.
In conclusion, Bcc strain resistance to many antibiotics poses a
problem for immunocompromised individuals (62, 63). For ex-
ample, as Bcc strains colonize CF lungs in the later stages of the
disease, patients exhibit a greater decline in pulmonary function
and an increase in mortality (64). Our data have shown that
SPLUNC1 affects J2315 by (i) bacteriostatic effects to reduce
growth and (ii) antibiofilm activity to prevent and reduce biofilm
formation via its 4 and 6 helixes. Further investigation into
these helixes may provide novel therapies for treating Bcc infec-
tions. While the impact of CF lung disease on SPLUNC1-Bcc in-
teractions is not currently known, our data suggest that under-
standing this phenomenon may have important implications for
CF lung disease.
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